Company Overview - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for narcolepsy [5] - The company reported a total revenue of $825.94 million and a net income of $185.68 million for the trailing twelve months (TTM) [4] - The company has 268 employees and experienced a 1-year price change of -5.92% as of January 31, 2026 [4] Recent Executive Transactions - Sandip Kapadia, the Chief Financial Officer, sold 3,746 shares on January 26, 2026, for approximately $139,171 [1][2] - Following this transaction, Kapadia's direct holdings decreased to 24,521 shares from over 127,000 shares in March 2023 [8] - The transaction value was based on a weighted average purchase price of $37.15, with a post-transaction value of $916,105 based on the market close of $37.36 [2] Financial Performance and Outlook - Harmony Biosciences expects to achieve over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [9] - The company has other medications in advanced development stages, projected to sustain operations into 2040 [10] - A 10% revenue increase is anticipated for 2025, indicating strong financial results and a positive outlook for investors [10] Investor Implications - Despite the recent sale by Kapadia, Harmony Biosciences' financials remain strong, particularly highlighted by a robust Q3 2025 net income, the highest since Q3 2022 [7] - The recent sale size of 3,746 shares is significantly below Kapadia's median sale size of 13,494 shares, suggesting a potential for further material sales [8]

Core Insights - Harmony Biosciences has shown promising financial performance, but the CFO, Sandip Kapadia, sold all her direct equity ownership in January 2026, raising questions about insider sentiment [1][6]. Financial Overview - As of January 31, 2026, Harmony Biosciences' stock price was $35.52, with a market capitalization of $2.1 billion, revenue of $825.94 million, and net income of $185.68 million [4]. - The transaction involved the sale of 20,961 shares for approximately $752,800, executed at a weighted average price of $35.92 per share [2][9]. Company Profile - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for treating narcolepsy [5]. Future Outlook - The company anticipates over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [7]. - Other medications in advanced development stages are projected to sustain revenue generation into 2040, with a 10% increase in 2025 [8]. Insider Trading Context - Kapadia's sale fully liquidated her direct holdings, which had previously been reduced from 72,948 shares to zero over the past year [9]. - The sale price was slightly below the market close of $36.41 on the transaction date and below the current share price of $36.62 as of January 31, 2026 [9].